Key Highlights

● CELC shares closed at $65.78 on October 7, 2026, down 7.68% on the day.

● No clinical trial update, regulatory development, Earnings report, financing, partnership, or analyst action has been verified as the driver.

● Clinical-stage biotechnology shares are among the most volatile in the market, swinging on shifts in risk appetite even without company news.

● The 10-year Treasury Yield reached roughly 5.35%, its highest since 2002, a particular headwind for pre-revenue biotech.

Celcuity (NASDAQ:CELC), the clinical-stage biotechnology company focused on targeted cancer therapies and its companion molecular-diagnostic technology, declined in the most recently completed US session on Wednesday, October 7, 2026. The shares closed at $65.78, down 7.68% on the day, a sharp move for a development-stage biotech.

No Confirmed Catalyst, a Volatile Profile

No confirmed company-specific catalyst explains the decline. No clinical trial update, regulatory development, earnings report, financing, partnership, or analyst action has been verified as the driver on October 7. Clinical-stage biotechnology shares are among the most volatile in the market, since their value rests almost entirely on the future prospects of drug candidates that have not yet reached commercialization.

A Particular Headwind for Pre-Revenue Names

Rising long-term rates are a particular headwind for pre-revenue biotech companies, because their potential cash flows lie far in the future and are discounted more heavily as rates climb. Breadth on the day underscored how indiscriminate the selling was, with roughly two-thirds of US issues declining and the Russell 2000 falling about 1.31%.

A Sector-Wide Repricing, Not a Confirmed Event

The clearest statement available is this: Celcuity shares fell sharply amid a biotech risk-off environment driven by surging Treasury yields, with nothing in company filings pointing to any other cause.